Unraveling the associations of age and menopause with cardiovascular risk factors in a large population-based study by unknown
RESEARCH ARTICLE Open Access
Unraveling the associations of age and
menopause with cardiovascular risk factors
in a large population-based study
A. C. de Kat1,2, V. Dam2, N. C. Onland-Moret2, M. J. C. Eijkemans2, F. J. M. Broekmans1 and Y. T. van der Schouw2*
Abstract
Background: Although the association between menopause and cardiovascular disease (CVD) risk has been
studied extensively, the simultaneous role of chronological aging herein remains underexposed. This study aims to
disentangle the relationships of menopausal status and chronological aging with CVD risk factors in the largest
study population to date.
Methods: In this cross-sectional study, CVD risk factors were compared between women with a different
menopausal status within the same yearly age strata. The study population comprised female participants of the
baseline visit of the population-based LifeLines Cohort Study. A total of 63,466 women, aged between 18 and
65 years, was included. Of them, 39,379 women were considered to be premenopausal, 8669 were perimenopausal,
14,514 were naturally postmenopausal, and 904 were surgically postmenopausal.
Results: Compared to postmenopausal women aged 45 years, average total cholesterol (TC) and low-density
lipoprotein cholesterol (LDL-c) were 0.5 and 0.4 mmol/L higher, respectively, in postmenopausal women aged 50.
Systolic and diastolic blood pressure levels were 4 and 1 mmHg higher, respectively. At all ages between 46 and
55 years, and after adjustment for confounders, naturally postmenopausal women had 0.2 to 0.4 mmol/L higher TC
and 0.1 to 0.3 mmol/L higher LDL-c levels compared to premenopausal women in the same age range. Systolic blood
pressure levels were up to 4 mmHg lower in naturally post- compared to premenopausal women at all ages between
29 and 52 years. Body mass index levels were up to 3.2 kg/m2 higher in women with surgical menopause compared to
all other women between the ages 32 and 52 years. All aforementioned results were statistically significant.
Conclusions: Chronological age and menopausal status are both independently associated with CVD risk factors.
Based on the comparatively smaller observed differences associated with menopausal status than with chronological
aging, the significance of a more unfavorable lipid profile in a later reproductive stage may be less obvious than
previously thought.
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Background
Menopause is the final result of the continuous decline
of ovarian reserve, marking the end of a woman’s repro-
ductive lifespan. An earlier age of reaching menopause is
considered to be associated with an increased risk of car-
diovascular disease (CVD) [1, 2], but the mechanisms
through which menopause is associated with CVD
remain unclear. The menopausal transition and post-
menopausal status have been associated with adverse
CVD risk factor levels [3–10], but studies have recently
contended that chronological aging or prior CVD risk
play a more important role [11–13].
As postmenopausal women are, by definition, older
than premenopausal women, it is challenging to separate
the effects of biological aging from the various phases of
the reproductive aging process [14]. This problem was
previously circumvented by exclusively studying 53-year-
old women born within the same week [7],
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longitudinally estimating the rate of change of CVD risk
factors in the time surrounding the final menstrual
period [6, 15], or comparing blood pressure levels be-
tween women in biannual age strata [16]. However, as
the menopausal transition occurs over several years, its
longitudinal effects can be ascribed to both aging and
menopausal status in the same participant. The currently
available studies were furthermore not able to assess the
individual effects of chronological and reproductive
aging over a large age interval.
In this study, we aimed to disentangle the associations
of menopausal status and chronological aging with CVD
risk factors over a wide age range. To this end, we com-
pared levels of CVD risk factors with menopausal status,




For our study population, there were 80,853 potentially
eligible women between 18 and 65 years old who partici-
pated in the baseline examination of the LifeLines
Cohort Study. Lifelines is a multi-disciplinary prospect-
ive population-based cohort study examining, in a
unique three-generation design, the health and health-
related behaviors of 167,729 persons living in the north
of The Netherlands. It employs a broad range of investi-
gative procedures in assessing the biomedical, socio-
demographic, behavioral, physical and psychological fac-
tors which contribute to the health and disease of the
general population, with a special focus on multi-
morbidity and complex genetics [17, 18]. The cohort
participants were recruited through general practitioner
registrations between 2006 and 2013. Cohort members
are examined at baseline and will be prospectively
followed up with visits in 5-year intervals and question-
naires every 1.5 years. The current study was based on
information from the baseline examination, which in-
cludes a questionnaire, anthropometric measurements
and blood withdrawal. All participants gave written in-
formed consent [19] and ethical approval was granted by
the medical ethics committee of University Medical
Center Groningen [18]. LifeLines is a facility that is open
for all researchers. Information on application and data
access procedure is summarized on www.lifelines.net.
Menopausal status assessment
Women with an intra-uterine contraceptive device
(n = 2445, 3.0%), who previously underwent a hyster-
ectomy (n = 4937, 6.2%), and/or who reported never
having had a regular menstrual cycle (n = 4780, 5.9%)
were excluded, leaving 73,662 women. Participants were
then divided into groups based on menopausal status,
which were defined as premenopausal, perimenopausal,
naturally postmenopausal or surgically menopausal.
Group allocation was based on baseline questionnaire in-
formation and followed the Stages of Reproductive Aging
Workshop (STRAW) criteria [20]. Women with a cur-
rently regular menstrual cycle (n = 39,379, 53.4%) were
classified as premenopausal. Women with an irregular
menstrual cycle since several months (n = 7661) or
years (n = 1260; total n = 8669, 11.8%) were considered
to be perimenopausal. Women who answered that they
were postmenopausal when asked about cycle regularity,
and with a date of last menstruation being more than
1 year before the visit (n = 14,514, 19.7%), were consid-
ered to be naturally postmenopausal. Women who re-
ported having had a bilateral oophorectomy (n = 904,
6.7%) were classified as surgically postmenopausal.
The reproductive status of 5293 (7.2%) women could
not be determined. This left 63,466 women in the
study population.
Cardiovascular risk factor assessment
At the baseline examination, height and weight were
measured by trained staff, from which body mass index
(BMI; in kg/m2) was calculated. Systolic and diastolic
blood pressure (SBP and DBP) were measured 10 times
during 10 minutes using a Dynamap PRO (GE Healthcare,
Freiburg, Germany) [18], from which the average values
were used. The baseline examination furthermore in-
cluded fasting venous blood withdrawal. Directly after
blood withdrawal, prespecified biomarkers in each fasting
blood sample were routinely assessed at the in-house la-
boratory of the University Medical Center Groningen.
Serum levels of total cholesterol (TC) and high-density
lipoprotein cholesterol (HDL-c) were assessed with an en-
zymatic colorimetric method, low-density lipoprotein chol-
esterol (LDL-c) was assessed with a colorimetric method
and triglyceride (TG) levels were measured with a colori-
metric ultraviolet method, with a Roche Modular P chemis-
try analyzer (Roche, Basel, Switzerland). Fasting blood
glucose was assessed with a hexokinase method [21].
Other variables
The questionnaires additionally contained questions
about hormonal contraception or postmenopausal hor-
mone therapy (HT) use and smoking status. Participants
were asked whether they had ever or were currently
using oral contraceptives, a hormonal intrauterine de-
vice, contraceptive injection (henceforth altogether re-
ferred as hormonal contraception) or HT. Current use
included any use in the prior month. Smoking status
was assessed by asking participants whether they were
current smokers or had smoked the previous months.
Current and ever smokers were furthermore asked about
the total duration and daily frequency of smoking. For
this study, smoking status was defined as current smoker
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(yes or no), including women who had smoked up until
the prior month.
Women who were pregnant at the time of examin-
ation (n = 109, 0.1%) were asked to fill out the question-
naire about the period preceding their pregnancy. They
completed their baseline visit at least 6 months after
their pregnancy and 3 months after ceasing to breast-
feed, at which point the questionnaire was handed in
and blood withdrawal occurred.
Data analysis
For all variables of interest, the number of complete
cases was 60,811 (96%) and missing information per
variable did not exceed 1%. Missing values were imputed
by conditional multiple imputation with 10 iterations,
through predictive mean matching for continuous vari-
ables and proportional odds for categorical variables. All
CVD risk factor variables, with the exception of TG,
were normally distributed. As the distribution of TG
levels was right-skewed, TG levels were log-transformed.
Baseline characteristics were presented across meno-
pausal status groups as mean ± SD or n (%), unless
stated otherwise.
To gain a first insight in differences in CVD risk factor
levels between the menopausal status categories inde-
pendently of age, a linear regression analysis was per-
formed within each 1-year age stratum for each
outcome, with premenopausal women as the reference
category. Women below the age of 34 were all included
in a 34-years and younger group, due to the relative lack
of postmenopausal women before this age. In a similar
fashion, women above age of 56 were all included in a
56-years and older age stratum. The regression analyses
were adjusted for smoking status, current hormonal
contraception and BMI due to their potential association
with both menopausal status and CVD risk factors. Be-
cause BMI was considered to be both a potential con-
founder and CVD risk factor, a model with BMI as an
outcome was also fit, which adjusted for smoking and
hormonal contraception use only. Models were further-
more adjusted for antihypertensive and lipid-lowering
medication.
The objective of investigating an independent associ-
ation of both calendar age and menopausal status with
CVD risk factor levels was addressed by creating a linear
regression model for each CVD risk factor as an out-
come, with menopausal status and age as independent
covariables. In order to adjust for smoking status, hor-
monal contraception use, antihypertensive or lipid-
lowering medication and BMI (except in the case of
BMI as a CVD risk factor outcome), these parameters
were additionally added to the model. To test whether
the association with age differed between the meno-
pausal status groups, we included an interaction term of
menopausal status with age in the model and tested its
significance with an analysis of variance (ANOVA).
Furthermore, in order to take into account a potential
non-linear relationship of age with CVD risk factors, re-
stricted cubic splines for age were added to the model
[22, 23]. The model was then tested for non-linearity
with an ANOVA analysis. Using the resulting best fitting
model (excluding the interaction term or splines if the
interaction term or test for non-linearity were non-
significant), the adjusted values for each outcome were
plotted against age for each menopausal status group.
All statistical analyses were performed with R (www.
r-project.org), version 3.1.3. Multiple imputation was
done using the ‘mice’ library, using a prediction
matrix with all determinants, outcomes and con-
founders [24]. The regression models were fitted with
the fit.mult.impute function from the ‘Hmisc’ library.
Sensitivity analyses
We performed four sensitivity analyses. First, the ana-
lyses described above were repeated after including
women with missing reproductive status information, by
assigning them to menopausal groups based on their
age, similar to the methods by Clavel-Chapelon et al.
[25]. Secondly, the analyses were repeated after exclud-
ing women who reported current use of cholesterol- or
blood pressure-lowering medication. Thirdly, the ana-
lyses were performed with only inclusion of women who
reported an irregular cycle ‘since several months’ as the
perimenopausal group. Finally, as the classification of
the STRAW criteria for the whole study population was
based on the answers to the question of cycle regularity
and menopause, hormonal contraception and HT use
were not taken into account for this determination. To
assess the differences between the menopausal status
groups independently from exogenous hormone use,
women who had ever used HT or currently used hormo-
nal contraception were excluded from analysis.
Patient involvement
The development of the research question and study de-
sign occurred without the involvement of patients. The
research question fits within the scope of healthy aging
in the general population, an objective set by LifeLines.
Results
In Table 1, the number of women in each age stratum
and menopausal status group is listed. Characteristics
for women in each reproductive category are presented
in Table 2. Mean age increased over the pre-, peri-, and
postmenopausal groups, and so did the mean levels of
all CVD risk factors. Hormonal contraception usage de-
creased over the pre-, peri- and postmenopausal groups,
with the lowest percentage of users in the surgically
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Table 1 Number of study participants in each menopausal status group per annual age stratum
Age stratum Premenopausal Perimenopausal Naturally postmenopausal Surgically postmenopausal Total
18 726 32 1 0 759
19 561 19 2 0 582
20 552 35 3 0 590
21 638 29 8 1 676
22 655 50 4 0 709
23 670 50 7 0 727
24 704 51 14 0 769
25 813 79 10 0 902
26 1138 119 26 1 1284
27 1064 120 25 0 1209
28 982 101 19 0 1102
29 971 119 19 1 1110
30 950 107 27 0 1084
31 995 116 28 2 1141
32 1028 119 42 3 1192
33 1070 110 32 1 1213
34 1118 99 39 2 1258
35 1151 113 54 1 1319
36 1235 138 70 5 1448
37 1369 134 83 8 1594
38 1464 145 63 6 1678
39 1606 153 108 15 1882
40 1731 187 95 7 2020
41 1796 245 119 11 2171
42 1860 248 121 16 2245
43 1783 352 135 22 2292
44 1781 380 137 19 2317
45 1740 490 157 28 2415
46 1577 535 208 40 2360
47 1489 659 290 39 2477
48 1337 743 392 43 2515
49 1148 788 508 61 2505
50 898 795 703 51 2447
51 467 565 691 37 1760
52 134 233 464 18 849
53 69 169 556 22 816
54 57 123 653 32 865
55 29 62 802 24 917
56 14 32 886 23 955
57 4 16 870 28 918
58 1 6 902 38 947
59 3 1 876 47 927
60 1 1 900 29 931
61 0 0 883 30 913
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postmenopausal group. The vast majority of women
who reported ever using HT (3% of the study popula-
tion) were postmenopausal (77%), with the highest per-
centage (64%) in the surgical menopause group. In the
premenopausal group, 203 (0.5%) women said to have
ever used HT, but reported a currently regular menstrual
cycle. In the naturally postmenopausal group, median
age (interquartile range, IQR) at menopause was 51 (46–
53) years.
For all CVD risk factors studied, the association be-
tween age and risk factor level was significantly non-
linear (P value for non-linearity < 0.001 in all cases), so
all models included restricted cubic splines for age. In
addition, for all CVD risk factors besides SBP and glu-
cose there was a significant interaction between age and
menopausal status (P values for the interaction term
ranged between < 0.001 and 0.01), indicating that the
magnitude of the differences in these risk factor levels
between menopausal status groups varied with age. The
models including cubic splines and the interaction term
had a better fit than the models without, assessed by
comparison of the Akaike’s Information Criterion. All
model residuals were furthermore normally distributed.
Since a single regression coefficient cannot be estimated
due to the splines and interactions, the fully adjusted
mean levels with 95% confidence interval (CI) bands of
all CVD risk factors are displayed for each menopausal
status group with age in Fig. 1a–h.
Between ages 29 and 52 mean SBP levels adjusted for
hormonal contraception use, smoking and BMI were sig-
nificantly lower in the naturally postmenopausal group
compared to the three other menopausal status groups,
as there was no overlap of CIs (Fig. 1a). Compared to
the premenopausal group, fully adjusted SBP levels were
between 2.6 and 4.0 mmHg lower in the naturally post-
menopausal group. Similar results were found with the
regression analyses within each age stratum (Additional
file 1: Table S1 displays the regression coefficients with
Table 1 Number of study participants in each menopausal status group per annual age stratum (Continued)
62 0 1 817 52 870
63 0 0 821 37 858
64 0 0 790 48 808
65 0 0 84 56 140
Total 39397 8669 14514 904 63466
Table 2 Characteristics per menopausal status group
Premenopausal Perimenopausal Naturally postmenopausal Surgically postmenopausal
n = 39,397 n = 8669 n = 14,514 n = 904
Baseline
Age, years 36.9 ± 8.1 45.0 ± 8.1 55.3 ± 7.4 52.7 ± 8.1
Age range, years 18–60 18–62 18–65 21-65
Current hormonal contraception use 18,526 (47.6) 1938 (22.7) 1787 (12.6) 825 (2.6)
Current smoker 8125 (21.0) 1969 (22.9) 2751 (19.1) 165 (18.4)
Antihypertensive medications 1559 (4.0) 608 (7.0) 2356 (20.3) 182 (20.3)
Lipid-lowering medications 388 (1.0) 178 (2.1) 1222 (8.4) 92 (10.2)
Ever HT use 203 (0.5)a 275 (3.2) 1315 (9.1) 253 (28.4)
Outcome
BMI, kg/m2 25.2 ± 4.6 26.0 ± 4.9 26.2 ± 4.5 27.3 ± 5.0
SBP, mmHg 119 ± 13 121 ± 14 125 ± 16 126 ± 16
DBP, mmHg 71 ± 9 72 ± 9 73 ± 9 72 ± 9
TC, mmol/L 4.7 ± 0.8 5.0 ± 0.9 5.6 ± 1.0 5.5 ± 1.0
LDL-c, mmol/L 2.9 ± 0.8 3.1 ± 0.8 3.6 ± 0.9 3.5 ± 0.9
HDL-c, mmol/L 1.6 ± 0.4 1.6 ± 0.4 1.7 ± 0.4 1.6 ± 0.4
TG, mmol/L 1.0 ± 0.5 1.0 ± 0.6 1.1 ± 0.6 1.2 ± 0.7
Glucose, mmol/L 4.8 ± 0.6 4.9 ± 0.7 5.0 ± 0.8 5.1 ± 1.0
Values given in mean ± SD or n (%)
aAll reported a currently regular cycle
HT hormone replacement therapy, BMI body mass index, SBP systolic blood pressure; DBP diastolic blood pressure, TC total cholesterol, LDL-c low-density lipoprotein
cholesterol, HDL-c high-density lipoprotein cholesterol, TG triglycerides
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Fig. 1 (See legend on next page.)
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95% CI for the linear regression analyses in each age
stratum for SBP). With regard to chronological aging,
compared to age 45, adjusted SBP levels at age 50 were
between 3.0 to 3.8 mmHg higher on average (Table 3).
No distinct pattern of differences between menopausal
stages within the age bands was observed for DBP
(Fig. 1b, Additional file 1: Table S2). Adjusted DBP levels
in all menopausal status groups were between 0.9 and
1.6 mmHg higher at age 50 compared to age 45 (Table 3).
Fully adjusted mean TC and LDL-c levels were
0.1 mmol/L higher in the perimenopausal group com-
pared to the premenopausal group, and 0.2–0.4 mmol/L
higher in the naturally postmenopausal group compared
to the premenopausal group across the range of 45–55
years, which reached statistical significance (Fig. 1c). Be-
tween 37 and 49 years, adjusted TC levels were 0.2–
0.4 mmol/L higher in the surgically postmenopausal
group compared to women in the premenopausal group,
and significantly higher than all three other groups
(Fig. 1c). Between 46 and 55 years, adjusted LDL-c levels
in the peri- and naturally postmenopausal groups were
0.1 and 0.3 mmol/L, respectively. Surgically postmeno-
pausal women had significantly higher adjusted LDL-c
levels than all other women between the ages of 38 and
49. Linear regression analyses within the age strata
echoed these results (Additional file 1: Table S3 and
Table S4). With respect to chronological aging, the aver-
age adjusted difference in TC and LDL-c levels between
45 and 50 years ranged from 0.2 to 0.5 and 0.2 to
0.4 mmol/L, respectively (Table 3).
No clear differences were observed in mean adjusted
HDL-c or glucose levels between the menopausal status
groups at all ages (Fig. 1e, f, Additional file 1: Table S5 and
Table S6). Compared to women aged 45 years, mean
adjusted HDL-c and glucose levels were 0.0–0.1 mmol/L
higher at age 50, dependent on menopausal status
group (Table 3).
Fully adjusted mean TG levels were up to 12% higher
in surgically postmenopausal women compared to pre-
menopausal women between the ages 42 and 53.
Between the ages 32 and 52, BMI levels were up to
3.2 kg/m2 higher in surgically postmenopausal compared
to premenopausal women. In these age ranges, TG and
BMI levels were significantly higher in surgically post-
menopausal women compared to women in all other
menopausal status groups (Fig. 1 g, h). In contrast, com-
pared to premenopausal women, TG levels were 5–22%
lower in postmenopausal women between the ages of 30
and 48. Similar results were found in the linear regres-
sion analyses in each age stratum, although the differ-
ences with the surgically postmenopausal group were
not significant, possibly due to lack of power (Additional
file 1: Table S5 and Table S6). At age 50, TG levels were
0.1 mmol/L higher in all menopausal status groups com-
pared to age 45 (Table 3). Adjusted BMI levels were ei-
ther the same or between 0.1 and 0.4 kg/m2 lower at age
50 compared to age 45, depending on the menopausal
status group (Table 3).
Sensitivity analyses
The sensitivity analyses are summarized for each out-
come in Additional files 2, 3, 4, 5, 6, 7, 8 and 9:
Figures S1–Figure S8. First, inclusion of the 5293
women with an age-based reproductive status did not
(See figure on previous page.)
Fig. 1 a–h Associations of adjusted cardiovascular risk factors with age per menopausal status group. Cardiovascular risk factor levels were
adjusted for age, oral contraceptive use, smoking status and body mass index. The premenopausal status group comprised a total of 39,379
women, whereas the perimenopausal group comprised 8669 women, the naturally postmenopausal group 14,514 women, and the surgically
postmenopausal group 904 women. a Systolic blood pressure, b Diastolic blood pressure, c Total cholesterol, d LDL-cholesterol, e HDL-cholesterol,
f Glucose, g Triglycerides and h Body mass index
Table 3 Average absolute differences in adjusted risk factors between women aged 45 and 50 years
Premenopausal Perimenopausal Naturally postmenopausal Surgically menopausal
Difference in adjusted risk factor levels (95% CI) between women aged 45 and 50 years
SBP, mmHg 3.8 (3.6 to 3.9) 3.6 (3.6 to 3.7) 3.7 (3.4 to 4.1) 3.0 (2.5 to 3.5)
DBP, mmHg 0.9 (0.8 to 1.0) 1.0 (1.0 to 1.0) 1.4 (1.2 to 1.6) 1.6 (1.2 to 1.9)
TC, mmol/L 0.2 (0.2 to 0.3) 0.3 (0.3 to 0.3) 0.5 (0.5 to 0.5) 0.2 (0.1 to 0.2)
LDL-c, mmol/L 0.2 (0.2 to 0.2) 0.2 (0.2 to 0.2) 0.4 (0.3 to 0.4) 0.1 (0.0 to 0.1)
HDL-c, mmol/L 0.0 (0.0 to 0.0) 0.1 (0.1 to 0.1) 0.1 (0.1 to 0.1) 0.1 (0.0 to 0.1)
Glucose, mmol/L 0.1 (0.1 to 0.1) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.1) 0.1 (0.1 to 0.1)
TG, mmol/L 0.1 (0.1 to 0.1) 0.1 (0.1 to 0.1) 0.1 (0.1 to 0.1) 0.1 (0.1 to 0.1)
BMI, kg/m2 0.0 (–0.0 to 0.1) −0.1 (–0.1 to –0.1) −0.3 (–0.4 to –0.2) −0.4 (–0.6 to –0.2)
SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, LDL-c low-density lipoprotein cholesterol, HDL-c high-density lipoprotein cholesterol,
TG triglycerides, BMI body mass index
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alter the results. Second, the exclusion of women who
used cholesterol- or blood pressure-lowering medication
(n = 1880 and n = 4705, respectively) also did not alter the
results, although the confidence interval of the surgical
menopause group became wider. Third, excluding 1260
women in the perimenopausal group with an irregular
cycle since several years additionally did not alter the
nature of the results for the perimenopausal group.
Fourth, exclusion of women using hormonal contra-
ception (n = 23,076) and HT (n = 2056) caused an ex-
pected widening of the confidence intervals due to
the reduced power. This did not affect the overall results,
with the exception of a more marked difference in TC,
LDL-c and TG levels between young pre- and postmeno-
pausal women (Additional files 4, 5 and 7: Figures S3,
Figure S4 and Figure S6).
Discussion
This study presents a unique view of reproductive aging,
independently of biological aging. We observed an asso-
ciation of CVD risk factors with menopausal status
within several clusters of annual age strata, indicating
that this relationship cannot be explained by the effects
of chronological aging alone. The magnitude of differ-
ences in CVD risk factors between menopausal status
groups did vary with age, highlighting the added role of
chronological aging. Based on these results, it seems
likely that both chronological aging and menopausal sta-
tus contribute to the CVD risk profile of aging women.
Naturally postmenopausal women had lower adjusted
SBP levels across a large age range than pre-, peri or sur-
gically postmenopausal women. Prior reports found a
later reproductive stage to be associated with increased
blood pressure [9, 16, 26], while others reported a lack of
any association after adjustment for age [6, 7, 13, 27, 28].
A longitudinal study in 193 women was the first to detect
a decreased SBP level in post- compared to premeno-
pausal women [29], hypothesizing that a diminishing ovar-
ian reserve exhibits a protective effect on increasing SBP
levels. By design, we cannot confirm this hypothesis,
but our results do contest previous reports of an ad-
verse blood pressure milieu in a peri- and postmeno-
pausal state [9, 16, 26].
Where lipid levels are concerned, previous findings are
less ambiguous and correspond well to our results. LDL-
c and TC levels are widely thought to be influenced by
the menopausal transition [6] or associated with meno-
pausal status [4, 5, 7, 10, 30–33]. In fact, the approxi-
mate difference in LDL-c levels of 11 mg/dL
(0.28 mmol/L) observed by Matthews et al. [6] between
the year preceding and following the final menstrual
period fits well within the range of our observations.
The decrease of estradiol throughout the menopausal
transition may not play a role in this regard, as TC and
LDL-c levels did not correlate with total or free estradiol
in 99 postmenopausal women [34]. On the other hand,
post-menopausal hormone therapy was associated with a
better lipid profile compared to placebo in a meta-
analysis of 28 trials [35]. Another explanation is the re-
duced activity of LDL-c receptors or lipoprotein lipase
in a postmenopausal state [36, 37].
In our population, differences in LDL-c and TC levels
between menopausal status groups only became evident
after the age of 45, after which LDL-c and TC levels
more sharply increased in the peri- and postmenopausal
groups. While a rapid increase in lipid levels was previ-
ously linked to the menopausal transition [4, 6], our re-
sults do suggest that chronological aging is equally
involved. Indeed, the adjusted difference in TC and
LDL-c values in the interval of 45–50 years was equal to
the maximum observed differences between the meno-
pausal status groups. It may be possible that, with
increasing age, the availability of compensatory mecha-
nisms to neutralize hyperlipidemia diminishes.
Surgically postmenopausal women, having undergone
a bilateral oophorectomy, had consistently higher BMI
and TG levels than the remaining women in the same
age stratum, the latter even after adjusting for BMI.
Others observed similar results [13, 38–42], with the
odds of becoming obese specifically increasing after bi-
lateral oophorectomy [41]. Interestingly, the adjusted
BMI of pre-, peri- and naturally postmenopausal women
hardly differed throughout the study population, which
is in line with previous findings [38], but at odds with
the observation that the menopausal transition influ-
ences fat distribution [15, 32].
For the past two decades, the relationship of meno-
pause with CVD risk factors has been studied exten-
sively through a myriad of ways. As most previous
research was based on smaller study populations, often
with significantly differing ages between pre- and post-
menopausal groups, we hope to provide a substantial
contribution to this age-old question with our study. Its
strengths are the use of a large study population, with
the ability to compare menopausal status groups and
CVD risk factors within yearly age strata, over a wide
age range. The protocolled assessment of study parame-
ters and relative lack of missing information limit the
chance of bias. Unfortunately, this was not quite the
case for the classification of menopausal status. It is
likely that some postmenopausal women using hormonal
contraception or HT were classified as premenopausal
due to the report of a regular cycle, and that some pre-
menopausal women with an irregular cycle were wrongly
classified as peri- or postmenopausal [43]. The exclusion
of women using exogenous hormones did not have an
obvious impact on the overall results, with the exception
that the lipid profile of young postmenopausal women
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appeared notably more unfavorable than the other
groups in this analysis. It is possible that this difference
is due to the putative benefits of hormone supplementa-
tion in young women in particular [44], or incorrect
classification of premenopausal women using hormonal
contraception as postmenopausal. In order to be consid-
ered postmenopausal, women had to report in the ques-
tionnaire that they had entered menopause in addition
to reporting an amenorrhea of at least a year, which
makes large-scale misclassification in this category less
likely. Moreover, the finding of very young women with
non-iatrogenic menopause corresponds to our observa-
tions in clinical practice and other Dutch cohort studies
and could therefore well be a realistic representation. Fi-
nally, due to the small number of women with surgical
menopause, there is insufficient power to separately
compare this group in all yearly strata. However, as this
group of women represents a different clinical entity
than natural menopause, we chose to maintain this
classification.
As this was a cross-sectional study, our observations
are limited to associations without drawing conclusions
on causality. A previous study was able to longitudinally
follow CVD risk factors [6], providing important infor-
mation on the changes surrounding the menopausal
transition. It is by definition impossible to distinguish
these changes from general aging throughout the meno-
pausal transition in the same participant, however, which
is why our current study provides an important contri-
bution from a different perspective. Although we are
able to confirm previous reports of differences in lipid
parameters based on menopausal status, the clinical im-
plications of the observed differences may be limited. A
reduction of LDL-c of 1.0 mmol/L was associated with a
22% decreased rate of major vascular events in an exten-
sive meta-analysis of individual patient data [45], but this
is difference is 2.5 to 10 times larger than menopause-
related differences in this study or the study by
Matthews et al. [6], and in fact more approximate to the
differences found with 20 years of chronological age. It
may be that the increased risk of cardiovascular events
observed in post-menopausal women, the causality of
which is a matter of debate in itself [11, 12, 46], is medi-
ated through other pathways such as oxidative stress
and inflammation [47]. A previous proposal of lipid
screening of women entering the menopausal transition
[6] may therefore not prove beneficial. That being said,
vigilance of changing lipid parameters in high-risk
women as they pass both biological and reproductive
aging thresholds may be worthwhile.
Conclusions
In conclusion, we observed independent associations
of both age and menopausal status with selected
CVD risk factors, mainly at the level of lipid metabol-
ism, in a large population-based cohort. The clinical
ramifications of a more unfavorable CVD risk factor
profile with the transition to menopause may be lim-
ited, however.
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